Liquidia Technologies (LQDA) Gets a Buy from BTIG

In a report released yesterday, Julian Harrison from BTIG reiterated a Buy rating on Liquidia Technologies (LQDAResearch Report), with a price target of $20.00. The company’s shares closed yesterday at $6.44.

According to TipRanks, Harrison is a 5-star analyst with an average return of 30.7% and a 68.42% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Outlook Therapeutics, Prometheus Biosciences, and United Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Liquidia Technologies with a $13.75 average price target, representing an 113.51% upside. In a report released on January 9, Needham also maintained a Buy rating on the stock with a $16.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

LQDA market cap is currently $416M and has a P/E ratio of -7.89.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.

Read More on LQDA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More